Idorsia Notes US Regulator's Plan to Lower Dual Orexin Receptor Antagonists Schedule

01:58 AM EDT, 08/11/2026 (MT Newswires) -- Idorsia (IDIA.SW) said Tuesday the US Drug Enforcement Administration recommended the reclassification of dual orexin receptor antagonists to the lowest schedule, potentially paving the way for enhanced patient access to the therapy. Dual orexin receptor antagonists are currently classified as Schedule IV under the Controlled Substances Act. Subject to a 30-day public comment period, the regulator could decide to move the drug class to Schedule V. The watchdog concluded that dual orexin receptor antagonists "do not produce physical or psychological dependence," following a scientific and medical evaluation, as well as a scheduling recommendation from the Department of Health and Human Services. The Swiss biopharmaceutical group's Quviviq, a dual orexin receptor antagonist, is approved to treat adult patients with chronic insomnia in the US.